On March 15, 2023 Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, reported that preclinical proof-of-concept data for EO-3021 will be highlighted in an oral presentation at the New Drugs on the Horizon special session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida (Press release, Elevation Oncology, MAR 15, 2023, View Source;utm_medium=rss&utm_campaign=elevation-oncology-to-present-at-the-american-association-of-cancer-research-aacr-annual-meeting-2023 [SID1234628647]). A poster highlighting the preclinical data for EO-3021, a potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, will also be presented at the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The oral presentation at this year’s AACR (Free AACR Whitepaper) New Drugs on the Horizon session is an exciting opportunity for Elevation Oncology to showcase preclinical data for EO-3021 as a potential best-in-class ADC targeting solid tumors expressing Claudin 18.2.," said David Dornan, Chief Scientific Officer of Elevation Oncology. "In addition, we look forward to presenting the preclinical data in more detail in a poster session at AACR (Free AACR Whitepaper) and remain on track to initiate a U.S. Phase 1 clinical trial evaluating EO-3021 during the second half of 2023."
Elevation Oncology will also present two posters on NRG1 fusions, including updated data from the Phase 2 CRESTONE study evaluating seribantumab in patients with solid tumors harboring NRG1 fusions. Elevation Oncology announced in January 2023 that it has paused enrollment in the Phase 2 CRESTONE study and further investment in seribantumab, pending entering a partnership.
Details of presentations at AACR (Free AACR Whitepaper) 2023 are as follows:
Title: EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers
Presentation: Oral Presentation by David Dornan, Chief Scientific Officer, Elevation Oncology
Session Type: Drug Development Track: Special Session – New Drugs on the Horizon Session: Part 3
Data and Time: Monday, April 17, 2023, 10:15AM-11:45AM ET
Title: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers
Authors: Mo Dan, et al.
Session Type: Poster Presentation
Session: Experimental and Molecular Therapeutics – Growth Factor Receptors as Therapeutic Targets
Abstract Number: 6300
Data and Time: Wednesday, April 19, 2023, 9:00AM-12:00PM ET
Title: Identification of NRG1 fusions in patients with solid tumors: Analysis from a real-world community oncology network
Authors: Emma G. Sturgill, et al.
Session Type: Poster Presentation
Session: Clinical Research Excluding Trials – Analyses Using Clinical and Genomic Databases
Abstract Number: 921
Data and Time: Sunday, April 16, 2023, 1:30PM-5:00PM ET
Title: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
Authors: Tejas Patil, et al.
Session Type: Poster Presentation
Session: Phase II Clinical Trials 2
Abstract Number: CT229
Data and Time: Tuesday, April 18, 2023, 9:00AM-12:30PM ET